And a reminder that $SRPT has yet to complete a confirmatory study of any of its conditionally approved exon-skipping drugs.What started out as a $2 stock, eventually morphed into a multi-billion dollar stock on the promise of 'curing' one (well, many similar) form of muscular dystrophy. Possbily not the first, but certainly one of the most memorable in recent times, of patient/advocate pressure on FDA to approve a drug with dubious data working.
Another company, Verastem, had its hat handed to them when its pancan drug 'failed'. Another disease that is a graveyard for drug companies.
No comments:
Post a Comment